Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -48.87
- Piotroski Score 3.00
- Grade Buy
- Symbol (AIM)
- Company AIM ImmunoTech Inc.
- Price $0.21
- Changes Percentage (-0.66%)
- Change -$0
- Day Low $0.21
- Day High $0.21
- Year High $0.62
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/31/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.64
- Trailing P/E Ratio -0.66
- Forward P/E Ratio -0.66
- P/E Growth -0.66
- Net Income $-28,962,000
Income Statement
Quarterly
Annual
Latest News of AIM
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Russia's claim of emissions in annexed Ukraine regions draws protests at COP29
By Valerie VolcoviciBAKU, Azerbaijan (Reuters) - Russia has included the territories it occupies in Ukraine in its recent greenhouse gas inventory report to the United Nations, drawing protests fr...
By Reuters | 5 hours ago -
Exclusive-Medical supply firm Medline aims to raise over $5 billion in 2025 IPO, sources say
Medline Industries, a medical supplies provider owned by private equity firms, plans to raise over $5 billion in a U.S. IPO in 2025, potentially valuing the company at $50 billion. The IPO is expected...
By Yahoo! Finance | 1 day ago -
Monmouth takes on SFA, aims to end 6-game slide
Monmouth seeks to break a losing streak against SFA. SFA excels in offensive rebounds led by Juhlawnei Stone, while Monmouth struggles on the road. Key players include Kyle Hayman for SFA and Abdi Bas...
By AP NEWS | 1 day ago
